HII Christens Destroyer Jack H. Lucas (DDG 125)

Written by Customer Service on March 26, 2022. Posted in Public Companies.

PASCAGOULA, Miss., March 26, 2022 (GLOBE NEWSWIRE) — HII (NYSE: HII) christened today pre-commissioning unit Jack H. Lucas (DDG 125) at the company’s Ingalls Shipbuilding division. Jack H. Lucas, a longtime resident of Hattiesburg, Mississippi, was the youngest Marine and youngest service member in World War II awarded the Medal of Honor. During a close firefight with Japanese soldiers, Lucas saved the lives of three Marines when he unhesitatingly placed himself on two grenades. “Jack H. Lucas made a selfless decision to choose others and country over self,” Ingalls Shipbuilding President Kari Wilkinson said. “Our Ingalls shipbuilders have a deep appreciation and respect for what sailors and Marines do on behalf of our nation. We are proud to support them and to provide them this remarkable ship, our first Flight III destroyer.” Chief...

Sanofi: Information concerning the total number of voting rights and shares – February 2022

Written by Customer Service on March 26, 2022. Posted in Public Companies.

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,527,121,390 €Registered office : 54, rue La Boétie – 75008 Paris – FranceRegistered at the Paris Commercial and Companies Registry under number 395 030 844 Date Total number of issued shares Number of real voting rights(excluding treasury shares) Theoretical number of voting rights (including treasury shares)* February 28, 2022 1,263,652,025 1,405,189,490 1,420,184,443 * Pursuant to article 223-11 of the Règlement général de l’Autorité des Marchés Financiers. This...

New GEM-3 Phase 3 Results for B-VEC Presented at 2022 American Academy of Dermatology Annual Meeting

Written by Customer Service on March 26, 2022. Posted in Public Companies.

PITTSBURGH, March 26, 2022 (GLOBE NEWSWIRE) — Krystal Biotech, Inc., (“Krystal Biotech”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, presented more detailed results from the GEM-3 Phase 3 study of beremagene geperpavec (B-VEC), an investigational, topical gene therapy, for the treatment of dystrophic epidermolysis bullosa (DEB), at the 2022 American Academy of Dermatology Annual Meeting in Boston, Mass. The data was presented by Peter Marinkovich, M.D., Director of the Blistering Disease Clinic at Stanford Health Care and Associate Professor of Dermatology at the Stanford University School of Medicine and primary investigator of the GEM-3 study, during the late-breaking research session. The full presentation is available in the Investors section of Krystal Biotech’s website. “We are very pleased...

Evelo Biosciences Presents Late-Breaking Oral Abstract on Data from Phase 2 Trial of EDP1815 in Psoriasis at 2022 American Academy of Dermatology Annual Meeting

Written by Customer Service on March 26, 2022. Posted in Public Companies.

CAMBRIDGE, Mass., March 26, 2022 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today presented a late-breaking oral abstract on data from a Phase 2 trial of EDP1815 in psoriasis at the 2022 American Academy of Dermatology (AAD) Annual Meeting, being held March 25-29 in Boston, Massachusetts. “We are proud to join the dermatology community at AAD to share the latest data from the clinical development of EDP1815 in psoriasis. The data being shared demonstrate the potential of Evelo’s SINTAX platform, and support progression towards registration trials for EDP1815,” said Douglas Maslin, M.Phil, M.B. B.Chir, Dermatology and Pharmacology Physician at Addenbrooke’s Hospital and...

Amryt Announces Positive Interim Analysis Data From Open Label Phase of EASE Phase 3 Trial in EB

Written by Customer Service on March 26, 2022. Posted in Public Companies.

Amryt Announces Positive Interim Analysis Data From Open Label Phase of EASE Phase 3 Trial in EB Late-breaking oral presentation at the American Academy of Dermatology Annual meeting 2022 Body surface area percentage of partial thickness wounds reduced from 12.1% to 5.4% after at least 15 months of treatment with Oleogel-S10 No new safety signals observed DUBLIN, Ireland, and Boston MA, March 26, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announced new positive clinical data from EASE, the largest Phase 3 trial in Epidermolysis Bullosa (EB). These data were presented during a late-breaking oral presentation at the American Academy of Dermatology (AAD) Annual Meeting 2022 held in Boston, MA. Professor...

Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis

Written by Customer Service on March 26, 2022. Posted in Public Companies.

Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis Dupixent significantly reduced itch at 12 weeks, and at 24 weeks nearly three times as many Dupixent patients experienced clinically meaningful reductions in itch and skin lesions There are currently no approved systemic treatments for prurigo nodularis; regulatory filings for prurigo nodularis planned in the first half of 2022 Paris and Tarrytown, N.Y. March 26, 2022. Detailed positive results from the Phase 3 PRIME2 trial evaluating the safety and efficacy of Dupixent® (dupilumab) was presented today in a late-breaking session at the American Academy of Dermatology (AAD) 2022 Annual Meeting. The companies previously announced topline results from PRIME2 and a second trial called PRIME investigating the use...

Islandsbanki hf.: Major Shareholder Announcement – The Capital Group Companies, Inc.

Written by Customer Service on March 26, 2022. Posted in Public Companies.

Enclosed is a major shareholder announcment from The Capital Croup Companies, Inc. Contacts Investor Relations – Margrét Lilja Hrafnkelsdóttir, ir@islandsbanki.is and tel: +354 844 4033 Public Relations – Edda Hermannsdóttir, pr@islandsbanki.is and tel: +354 844 4005 Íslandsbanki press releases If you wish to receive Íslandsbanki press releases by e-mail please register at: https://www.islandsbanki.is/en/article/email_list_ir About Íslandsbanki With a history that dates from 1875, Íslandsbanki is an Icelandic universal bank with a strong customer focus. The Bank believes in moving Iceland forward by empowering its customers to succeed – reflecting a commitment to run a solid business that is a force for good in society. Driven by the ambition to be #1 for service, Íslandsbanki’s banking model is led by three business divisions...

AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing

Written by Customer Service on March 26, 2022. Posted in Public Companies.

PHILADELPHIA, March 26, 2022 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that on March 24, 2022, it received a Staff determination letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company of the Staff’s determination to delist the Company’s securities from The Nasdaq Global Market due to its failure to regain compliance with the minimum $50,000,000 Market Value of Listed Securities required for continued listing as set forth in Listing Rule 5450(b)(2)(A) (the “ MVLS”), following the 180 calendar day compliance period. The Letter also indicates that the Company has not met the...

Magna Posts 2021 Annual Report

Written by Customer Service on March 26, 2022. Posted in Public Companies.

AURORA, Ontario, March 25, 2022 (GLOBE NEWSWIRE) — Magna International Inc. (TSX: MG; NYSE: MGA) today announced that its 2021 Annual Report, including Management’s Discussion and Analysis and Audited Consolidated Financial Statements, Annual Information Form (AIF) and Form 40-F, are now available on the company’s website, www.magna.com. Magna has also filed these documents with the Canadian Securities Administrators (accessible through its website at www.sedar.com) and the U.S. Securities and Exchange Commission (accessible through its website at www.sec.gov/edgar). Our 2022 Annual and Special Meeting of Shareholders will be held on Tuesday May 3, 2022, commencing at 10:00 a.m. (Eastern Daylight Time). The meeting is being conducted as a virtual-only meeting accessible at www.virtualshareholdermeeting.com/mga2022. Magna...

CapStar Ranked Among Nation’s Highest Performing Banks

Written by Customer Service on March 26, 2022. Posted in Public Companies.

NASHVILLE, Tenn., March 25, 2022 (GLOBE NEWSWIRE) — CapStar Financial Holdings, Inc. (“CapStar”, the “Company”) (NASDAQ: CSTR), the parent company of CapStar Bank, was recently recognized by two leading industry observers as one of the nation’s highest-performing banks. Launched more than a decade ago to assess the performance of community banks and credit unions, S&P Global Market Intelligence ranked CapStar #18 among banks nationwide with assets between $3 billion and $10 billion for 2021 based on returns, growth, and efficiency, with a premium placed on the strength and risk profile of balance sheets. CapStar was the second highest ranked Southeast institution and Tennessee’s highest-ranking institution. Hovde Group, a boutique investment bank focused exclusively on the financial services sector, included CapStar among...

Day: March 26, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice